Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301

Clinical trial NCT05286762 · COMPLETED

Trial details

NCT number: NCT05286762
Sponsor: Cingulate Therapeutics
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

ADHD Attention Deficit Hyperactivity Disorder ADHD - Combined Type Attention Deficit Hyperactivity Disorder Combined Attention-deficit Hyperactivity Attention Deficit Hyper Activity

Start date: 2023-08-01
Primary completion: 2024-02-29
Enrollment: 103

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.